James R. Gruber - 11 Dec 2025 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Role
Chief Financial Officer
Signature
/s/ James R. Gruber
Issuer symbol
ETON
Transactions as of
11 Dec 2025
Net transactions value
-$77,169
Form type
4
Filing time
12 Dec 2025, 16:55:46 UTC
Previous filing
20 Aug 2025
Next filing
14 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gruber James R. Chief Financial Officer C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK /s/ James R. Gruber 12 Dec 2025 0001923165

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ETON Common Stock Tax liability $77,169 -4,542 -2.1% $16.99 215,713 12 Dec 2025 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETON Restricted Stock Units Award $0 +5,502 +2.7% $0.000000 210,255 11 Dec 2025 Common Stock 5,502 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units.
F2 The shares were sold in multiple trades at prices ranging from $16.94 to $17.07. The price reported above reflects the weighted average sales price.
F3 The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
F4 Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
F5 The restricted stock units vest immediately as of the award date.